MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) a international leader in specialized, analysis-driven pharmaceutical-high quality cannabis extraction, distillation and derivative merchandise, these days announced it will provide cannabis concentrate merchandise in Denmark to two new health-related cannabis shoppers beneath two separate white-label agreements. These shoppers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ initially provide agreements for the export of completed merchandise to Denmark.
Denmark granted individuals legal access to cannabis-primarily based medicinal merchandise two years ago as portion of a 4-year pilot plan. The plan supplies individuals with secure item access and national well being authorities with patient information that they can use to comprehend usage and efficacy. According to facts complied by New Frontier Information and the Danish Ministry of Well being, more than two,one hundred individuals (mainly females in between the ages of 42-64) received cannabis-primarily based medicinal merchandise from 429 prescribing physicians beneath this plan in 2019.
“The express objective of establishing a multi-jurisdictional, GMP-certified production capability is to lead the international cannabis market place for medicinal, wellness and adult use applications and these agreements represent one more step forward in realizing our ambitions,” mentioned Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish health-related market place with new and revolutionary health-related cannabis focused merchandise positions us for further development in Europe and adds to MediPharm Labs all-critical physique of know-how that we are leveraging to boost the style of our formulations for individuals and customers everywhere.”
Beneath the agreements, a single which has an initial two-year term and the second a a single-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil merchandise that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its shoppers to commence in October 2020, pending regulatory approval by applicable well being authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured quite a few quite eye-catching domestic and international provide agreements with higher high quality partners, now which includes new shoppers in Denmark,” mentioned Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new business enterprise wins are a clear and critical validation of our choice to construct a GMP certified cannabis extraction facility provide chain for globe markets and a testament to MediPharm Labs expanding profile and reputation. We appear forward to ramping up production beneath all of these agreements.”
MediPharm Labs Australia received its Very good Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in Might 2020, which enables it to sell cannabis APIs and completed merchandise to nations across the EU, which includes Denmark. The Organization entered into its initially European white-label cannabis provide agreement that similar month with Therismos Restricted.
About Denmark’s Healthcare Cannabis Marketplace
Denmark launched its 4-year health-related cannabis pilot plan on January 1st, 20181. Post-harvest Very good Manufacturing Processes (GMP) is essential for distribution of health-related cannabis merchandise in Denmarktwo.
By means of the plan, physicians can prescribe health-related cannabis for all purposes and are guided by suggestions in 4 locations: discomfort brought on by various sclerosis, discomfort brought on by spinal cord harm, side effects from chemotherapy therapy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an comprehensive assessment of literature as nicely as assessments of: cannabis schemes in the Netherlands, Canada and Israel preceding cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high quality cannabis oil and concentrates and sophisticated derivative merchandise using a Very good Manufacturing Practices certified facility with ISO common constructed clean rooms. MediPharm Labs has invested in an specialist, analysis-driven group, state-of-the-art technologies, downstream purification methodologies and objective-constructed facilities with 5 major extraction lines for delivery of pure, trusted and precision -dosed cannabis merchandise for its shoppers. By means of its wholesale and white label platforms, they formulate, customer-test, approach, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based merchandise to domestic and international markets. As a international leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
Sponsored Content material Release. Click for Complete Disclosure
Supply: https://www.financialbuzz.com/breaking-news-medipharm-labs-enters-denmark-health-related-cannabis-market place-secures-new-white-label-provide-shoppers/